Fol. Biol. 2006, 52, 45-46
https://doi.org/10.14712/fb2006052010045
Human Papillomavirus (HPV) and HPV-Associated Tumour Vaccines
References
1. , M. E. G., Rutherford, E., Hickling, J. K., Inglis, S. C. (1996) A recombinant vaccinia virus encoding human papillomavirus types 16 and 18 E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347, 1523-1527.
2. , J. (2002a) Therapeutic vaccines against HPV16associated tumors. Neoplasma 49, 285-289.
3. , J. (2002b) Animal models for development of therapeutic HPV16 vaccines (Review). Int. J. Oncol. 20, 207-212.
4. , J., Mikyšková, R., Vonka, V., Mendoza, L., Šímová, J., Šmahel, M., Indrová, M. (2003) Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine 21, 891-896.
<https://doi.org/10.1016/S0264-410X(02)00537-6>
5. , D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De Carvalho, N. S., Roteli-Martins, C. M., Teixeira, J., Blatter, M. M., Korn, A. P., Quint, W., Dubin, G. (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized control trial. Lancet 364, 1757-1765.
<https://doi.org/10.1016/S0140-6736(04)17398-4>
6. , A. M., Stern, P. L., Rankin, E. M., Sommer, H., Nuessler, V.,Schneider, A., Adams, M., Onon, T. S., Bauknecht, T., Wagner, U., Kroon, K., Hickling, J., Boswell, C. M., Stacey, S. N., Kitchener, H. C., Gillard, J., Wanders, J., Roberts, J. S., Zwierzina, H. (2002) Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin. Cancer Res. 8, 3676-3685.
7. , M., Šímová, J., Bubeník, J. (2006) Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-deficient and -proficient HPV16-associated tumours. Int. J. Cancer 118, 1836-1842.
<https://doi.org/10.1002/ijc.21546>
8. , L. J., Van Poelgeest, M. I., Davidson, E. J., Kwappenberg, K. M., Burt, D., Sehr, P., Pawlita, M., Man, S., Hickling, J. K., Fiander, A. N., Tristram, A., Kitchener, H. C., Offringa, R., Stern, P. L., Van Der Burg, S. H. (2004) Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin. Cancer Res. 10, 2954-2961.
<https://doi.org/10.1158/1078-0432.CCR-03-0703>
9. , R. (2006) The potential of human papillomavirus vaccines. New Engl. J. Med. 354, 1109-1112.
<https://doi.org/10.1056/NEJMp058305>
10. , A., van Dam, P. A., Fleuren, G. J., Kast, W. M., Melief, C. J. M., Trimbos, J. B. (1999) Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur. J. Cancer 35, 946-952.
11. , L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C., Lehtinen, M., Skjeldestad, F. E., Olsson, S. E., Steinwall, M., Brown, D. R., Kurman, R. J., Ronnett, B. M., Stoler, M. H., Ferenczy, A., Harper, D. M., Tamms, G. M., Yu, J., Lupinacci, L., Railkar, R., Taddeo, F. J., Jansen, K. U., Esser, M. T., Sings, H. L., Saah, A. J., Barr, E. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6, 271-278.
<https://doi.org/10.1016/S1470-2045(05)70101-7>
